Abstract
The focus on wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) is increasing because of novel treatment options. There is currently no report on a large number of Japanese patients with ATTRwt-CM. The study aimed to examine the characteristics and prognosis of ATTRwt-CM in Japan. Consecutive patients (78.5 ± 6.4 years old at diagnosis) with ATTRwt-CM diagnosed at Kumamoto University Hospital between December 2002 and December 2019 were retrospectively reviewed. Data, including demographic characteristics, co-morbidities, clinical manifestations at diagnosis, laboratory results, electrocardiographic and echocardiographic data, imaging and pathological findings, and treatment were obtained. Of 129 patients included in this study, 110 patients (85%) were male. The median period from initial symptom onset to diagnosis was 15.5 (2-75) months. Heart failure was the most common clinical manifestation leading to diagnosis (61%) and initial manifestations (49%). Of 106 patients, carpal tunnel syndrome was observed in 57 patients (54%), and the median period from initial symptom onset to diagnosis was 96 (48-120) months. Histopathological confirmation of transthyretin amyloid was achieved in 94 patients (73%), including 66 (51%)...Continue Reading
References
Jun 1, 1985·Journal of the American College of Cardiology·J L WillemsP Moret
Jan 24, 2002·Neurology·Mauro MondelliMariano Giacchi
Sep 20, 2005·Journal of the American College of Cardiology·Enrica PeruginiClaudio Rapezzi
Feb 21, 2007·European Heart Journal·Mihai GheorghiadeUNKNOWN OPTIMIZE-HF Investigators and Coordinators
Oct 30, 2008·BMC Public Health·Stefano MattioliFrancesco S Violante
Feb 22, 2011·Human Pathology·Takanao SueyoshiHiroshi Mizuta
Apr 24, 2013·Journal of the American Heart Association·Jennifer H PinneyHelen J Lachmann
Apr 12, 2014·JACC. Heart Failure·Selma F MohammedMargaret M Redfield
Jul 30, 2015·European Journal of Heart Failure·Hiroaki ShimokawaYasuhiko Sakata
Aug 1, 2015·European Heart Journal·Esther González-LópezPablo Garcia-Pavia
Aug 9, 2015·The American Journal of Cardiology·Gianluca Di BellaScipione Carerj
Dec 4, 2015·Circulation Journal : Official Journal of the Japanese Circulation Society·Hiroaki KusakaHisao Ogawa
Dec 15, 2015·Circulation·Lawreen H ConnorsDavid C Seldin
Feb 9, 2016·Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis·Michitaka NakagawaShu-Ichi Ikeda
Jul 9, 2016·Journal of the American College of Cardiology·Mathew S MaurerUNKNOWN THAOS Investigators
Aug 12, 2016·Circulation. Cardiovascular Imaging·Thomas A TreibelJames C Moon
Sep 3, 2016·Journal of the American College of Cardiology·Martha GroganAngela Dispenzieri
Sep 16, 2016·Scandinavian Journal of Work, Environment & Health·Yves RoquelaureBuisson Catherine
Mar 23, 2017·European Heart Journal·Esther González-LópezPablo Garcia-Pavia
Sep 5, 2017·ESC Heart Failure·Seiji TakashioKenichi Tsujita
Oct 12, 2017·European Heart Journal·Adam CastañoMathew S Maurer
Oct 20, 2017·European Heart Journal·Julian D GillmorePhilip N Hawkins
Nov 9, 2017·Journal of cardiology·Yasuhiro IzumiyaKenichi Tsujita
Nov 29, 2017·Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis·Yoshiki SekijimaYukio Ando
Aug 28, 2018·The New England Journal of Medicine·Mathew S MaurerUNKNOWN ATTR-ACT Study Investigators
May 11, 2019·Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis·Seitaro OdaYasuyuki Yamashita
Jun 7, 2019·Journal of the American College of Cardiology·Frederick L RubergMathew S Maurer
Jun 14, 2019·Circulation Journal : Official Journal of the Japanese Circulation Society·Kyohei MarumeKenichi Tsujita
Jul 6, 2019·Journal of the American College of Cardiology·Emil L FosbølFinn Gustafsson
Jul 16, 2019·JACC. Heart Failure·Ronald M WittelesPablo Garcia-Pavia